» Articles » PMID: 8143834

Lung Deposition of Budesonide Inhaled Via Turbuhaler: a Comparison with Terbutaline Sulphate in Normal Subjects

Overview
Journal Eur Respir J
Specialty Pulmonary Medicine
Date 1994 Jan 1
PMID 8143834
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

We wanted to evaluate whether lung deposition of budesonide and terbutaline sulphate differs, and to determine lung deposition of budesonide inhaled at different peak inspiratory flows, through Turbuhaler. Lung deposition of budesonide, a lipophilic substance, and of terbutaline sulphate, a hydrophilic substance, was therefore compared, after administration via an inspiratory flow-driven, multi-dose, powder inhaler (Turbuhaler, Astra Draco AB) to 10 healthy volunteers. The radionuclide 99mTc was used to label drug particles, and radioactivity, indicating drug deposition, was measured using a gamma camera. Budesonide was inhaled at a normal flow of 58 l.min-1 and at a slow flow of 36 l-min-1. At the faster flow, a mean +/- SD 27.7 +/- 9.5% of the metered dose was deposited in the lung and at the slower flow 14.8 +/- 3.3% was deposited (p < 0.001). Mean lung deposition of terbutaline sulphate inhaled at 57 l.min-1 was 27.0 +/- 7.7%. We conclude that inspiratory flow has an important effect on lung deposition, but water solubility appears to have no effect.

Citing Articles

Peak Inspiratory Flow and Inhaler Prescription Strategies in a Specialized COPD Clinical Program: A Real-World Observational Study.

Pankovitch S, Frohlich M, AlOthman B, Marciniuk J, Bernier J, Paul-Emile D Chest. 2024; 167(3):736-745.

PMID: 39384100 PMC: 11882739. DOI: 10.1016/j.chest.2024.09.031.


Modelling Drug Delivery to the Small Airways: Optimization Using Response Surface Methodology.

Min H, Payne S, Stride E Pharm Res. 2024; 41(6):1139-1148.

PMID: 38755398 PMC: 11525259. DOI: 10.1007/s11095-024-03706-1.


Budesonide Attains Its Wide Clinical Profile by Alternative Kinetics.

Brattsand R, Selroos O Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675463 PMC: 11055149. DOI: 10.3390/ph17040503.


Particulate bioaerogels for respiratory drug delivery.

Li H, Makatsoris C, Forbes B J Control Release. 2024; 370:195-209.

PMID: 38641021 PMC: 11847494. DOI: 10.1016/j.jconrel.2024.04.021.


Standardized inhalation capability assessment: A key to optimal inhaler selection for inhalation therapy.

Wu Y, Zhang J J Transl Int Med. 2023; 11(1):26-29.

PMID: 37223614 PMC: 10202017. DOI: 10.2478/jtim-2022-0073.